Background: Hemoglobin variability (Hb-var) has been associated with increased mortality both in non-dialysis dependent chronic kidney disease (NDD-CKD) and end-stage renal disease (ESRD) patients. However, the impact of Hb-var in advanced NDD-CKD on outcomes after dialysis initiation remains unknown. Methods: Among 11,872 US veterans with advanced NDD-CKD transitioning to dialysis between October 2007 through September 2011, we assessed Hb-var calculated from the residual SD of at least 3 Hb values during the last 6 months before dialysis initiation (prelude period) using within-subject linear regression models, and stratified into quartiles. Outcomes included post-transition all-cause, cardiovascular, and infection-related mortality, assessed in Cox proportional hazards models and adjusted for demographics, comorbidities, length of hospitalization, medications, estimated glomerular filtration rate (eGFR), type of vascular access, Hb parameters (baseline Hb [i.e., intercept] and change in Hb [i.e., slope]), and number of Hb measurements. Results: Higher prelude Hb-var was associated with use of iron and antiplatelet agents, tunneled dialysis catheter use, higher levels of baseline Hb, change in Hb, eGFR, and serum ferritin. After multivariable adjustment, higher prelude Hb-var was associated with higher post-ESRD all-cause and infection-related mortality, but not cardiovascular mortality (adjusted hazard ratios [95% CI] for the highest [vs. lowest] quartile of , and 0.93 [0.79-1.10], respectively). Conclusions: High pre-ESRD Hb-var is associated with higher mortality, particularly from infectious causes rather than cardiovascular causes. Further research is required to clarify the underlying mechanisms and true causal nature of the observed association.
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Introduction
Anemia is a frequent complication of chronic kidney disease (CKD) and is associated with worse outcomes in patients with CKD [1] . The introduction of erythropoiesis stimulating agents (ESAs) in 1989 has given clinicians the ability to increase hemoglobin (Hb) levels, yet targeting normal Hb levels did not result in better survival, but rather in increased cardiovascular events and mortality in patients with CKD [2] [3] [4] . Maintenance of a stable Hb within the narrow range currently recommended in patients with CKD often requires frequent ESA dosing changes that, in addition to other factors such as age, intercurrent diseases, and iron therapy [5, 6] , result in a continuous cycling of Hb levels in contrast to individuals with normal renal function whose Hb levels are held constant by oxygen delivery sensing feedback upon erythropoiesis. In recent years, observational studies have shown that higher Hb variability (Hb-var) is associated with adverse outcomes both in non-dialysis dependent CKD (NDD-CKD) and end-stage renal disease (ESRD) patients [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . However, to the best of our knowledge, no previous studies have examined the impact of Hb-var in late stage NDD-CKD on outcomes after dialysis initiation. Given the pervasive nature of anemia in this vulnerable population who experience the highest mortality immediately after the transition to dialysis and suffer from an exceptionally high health and economic burden [1, 17] , the question whether high Hb-var in the immediate pre-ESRD period is associated with post-transition mortality is of particular relevance. We therefore investigated the association of Hb-var in the pre-ESRD transition period with post-ESRD all-cause, cardiovascular, and infection-related mortality, using a large nationally representative cohort of US veterans with incident ESRD.
Materials and Methods

Study Population
We analyzed longitudinal data from the Transition of Care in CKD study, a retrospective cohort study examining US veterans with incident ESRD transitioning to dialysis from October 1, 2007, through September 30, 2011 [18-20] . A total of 52,172 US veterans were identified from the US Renal Data System (USRDS) [21] as a source population. The algorithm for the cohort definition is shown in online supplementary Figure 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000484356). We extracted all Hb values measured during clinical encounters in any Veterans Affairs (VA) facility; patients without Hb measurements (n = 23,088) were excluded. We also excluded patients with less than 3 Hb measurements recorded on different days within 6 months prior to dialysis initiation (i.e., 6-month "prelude period"; n = 17,068) and who were missing follow-up data (n = 144), resulting in an analytical sample of 11,872 patients.
Exposure Variable
The primary exposure of interest was Hb-var over the 6-month prelude period. Hb-var was defined as the residual SD calculated by within-subject linear regression models using all Hb values in each patient. We categorized the Hb-var values into quartiles (<0.46, 0.46-<0.69, 0.69-<0.96, and ≥0.96 g/dL), using the lowest Hb-var quartile as reference. The Hb-var level was also treated as a continuous variable to examine nonlinear associations by using a restricted cubic spline analysis. Baseline Hb level and average change in Hb (g/dL per month) were defined as the intercept and the slope estimated from the same regression models used to calculate Hb-var.
Covariates
Data from the USRDS Patient and Medical Evidence files were used to determine patients' baseline demographic characteristics and type of vascular access at the time of dialysis initiation. Information on comorbidities was extracted from the VA Inpatient and Outpatient Medical SAS Datasets [22] , using the International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic and procedure codes and Current Procedural Terminology codes, as well as from VA/Centers for Medicare and Medicaid Services (CMS) data. The Charlson Comorbidity Index score was calculated using the Deyo modification for administrative datasets, without including kidney disease [23] . Cardiovascular disease was defined as the presence of diagnostic codes for angina, coronary artery disease, myocardial infarction, or cerebrovascular disease. Medication data were collected from both CMS Data (Medicare part D) and VA pharmacy dispensation records [24] . Patients who received at least 1 dispensation of medications within the 6-month prelude period were recorded as having been treated with these medications. Laboratory data were obtained from VA research databases as previously described [25, 26] , and their baseline values were defined as the average of each covariate during the 6-month prelude period preceding dialysis initiation. Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation [27] .
Outcome Assessment
The co-primary outcomes of interest were all-cause, cardiovascular, and infection-related mortality after dialysis initiation. The start of the follow-up period was the date of dialysis initiation, and patients were followed up until death or other censoring events including kidney transplantation, loss of follow-up, or the last date of available follow-up (December 27, 2012, and October 6, 2011, for all-cause and cause-specific mortality, respectively) [18] [19] [20] . All-cause mortality data, censoring events, and associated dates were obtained from VA and USRDS data sources [21] . Cause-specific mortality data were obtained from USRDS. measurements over the 6-month prelude period, and eGFR and serum ferritin levels averaged over the 6-month prelude period. Variance inflation factors were calculated to examine substantial multicollinearity among these parameters, and values >5.0 were considered to indicate collinearity. The association between Hb-var and mortality was estimated using Cox proportional hazards models. Models were incrementally adjusted for the following potential confounders based on theoretical considerations: model 1 adjusted for age, sex, race/ethnicity, and marital status; model 2 additionally accounted for comorbidities (diabetes mellitus, cardiovascular disease, CHF, peripheral vascular disease, lung disease, peptic ulcer disease, liver disease, malignancy, and HIV/ AIDS), Charlson comorbidity index, and cumulative length of hospitalization during the 6-month prelude period as an indicator of sickness; model 3 additionally included medications (ESAs, intravenous or oral iron, vitamin D analogs, angiotensin-converting enzyme inhibitors s/ angiotensin receptor blockers , antiplatelet agents, and warfarin), eGFR, type of vascular access (arteriovenous fistula, arteriovenous graft, or catheter), baseline Hb, change in Hb, and number of Hb measurements over the 6-month prelude period. Tests for linear trend across quartiles were conducted by applying the median value of each quartile to relevant patients and modeling that variable as a continuous variable in the regression models. Restricted cubic spline models were used to investigate nonlinearity in fully adjusted associations between Hb-var and mortality.
Statistical Analysis
We performed several sensitivity analyses to evaluate the robustness of our main findings. The associations of Hb-var with outcomes were examined in subgroups of patients stratified by age, race, prevalent diabetes mellitus, cardiovascular disease, and CHF, eGFR, use of ESAs and iron, and number of Hb measurements over the 6-month prelude period. Potential interactions were formally tested by including relevant interaction terms. We also investigated whether accounting for serum ferritin levels further attenuates the Hb-var-mortality associations in the group of 8,605 patients with available serum ferritin measurements as an additional model (model 4). In order to account for the different Hb determinations between inpatient and outpatient settings, we further performed an additional analysis using at least 3 inpatient/outpatient Hb values separately to calculate the variability.
Compared to patients in the main cohort (n = 11,872), those who were excluded from the source cohort (n = 40,300) were older (71.6 vs. 66.0 years) and were less likely to be men (93.3 vs.
98.0%), African-American (20.9 vs. 35.4%), and diabetic (53.1 vs. 71.9%). Of the variables included in multivariable models, data points were missing for race (0.2%), eGFR (0.2%), vascular access type (6.4%), and serum ferritin (22.8%). Information about cause of death was also missing in 2,831 of the 5,711 (49.6%) who died in our study population (online suppl. Table 1) . Of the 11,872 patients in our study population, 11,088 (93.4%) had complete data available for the main adjusted multivariable model (model 3). Due to the relatively low proportion of missing information in the main model, missing data was not imputed. The reported p values are 2-sided and reported as significant at <0.05 for all analyses. All analyses were conducted using STATA/MP version 14 (STATA Corporation, College Station, TX, USA). The study was approved by the Institutional Review Boards of the Memphis and Long Beach VA Medical Centers, with exemption from informed consent.
Results
Baseline Characteristics
Overall, the mean ± SD age at baseline was 66.0 ± 11.1 years, 98.0% of patients were men, 35.4% were African American, and 71.9% were diabetic. The median (IQI) eGFR level was 13.1 (9.9-17.7) mL/min/1.73 m 2 . During the 6-month prelude period, patients had a median (IQI) of 8 (5-15) Hb measurements. The mean ± SD prelude Hb-var was 0.75 ± 0.45 g/dL. Baseline characteristics in the overall cohort and stratified by Hb-var quartiles are presented in Table 1 . Compared to patients with lower Hb-var, those with higher Hb-var tended to have a poorer risk profile (higher prevalence of comorbidities, longer cumulative length of hospitalization, and lower serum albumin and higher serum ferritin levels) and had lower BMI and higher eGFR levels. They were also more likely to initiate dialysis therapy with a catheter and use ESAs, iron, and antiplatelet agents. Table 2 shows the association of Hb-var with patient characteristics. After multivariable adjustment, history of peptic ulcer disease or malignancy, use of iron and antiplatelet agents, dialysis catheter use, and higher baseline Hb, change in Hb, number of Hb measurements, eGFR, and serum ferritin levels were associated with higher Hbvar. In contrast, older age and use of warfarin were associated with lower Hb-var.
Variables Associated with Prelude Hb-var
Association of Pre-ESRD Hb-var with Post-ESRD All-Cause Mortality
There were 5,711 all-cause deaths during a median follow-up of 2.1 years (IQI 1.2-3.3 years; total time at risk, DOI: 10.1159/000484356 26,748 patient-years) following dialysis initiation (crude incidence rate, 213.5 per 1,000 patient-years; 95% CI 208.0-219.2). Table 3 shows the multivariable-adjusted hazard ratios (HRs) associated with pre-ESRD Hb-var quartiles. In the demographically adjusted model, higher Hb-var quartiles were incrementally associated with higher all-cause mortality (p value for trend <0.001; Table  3 ). After further adjustment for other potential confounders, the association between Hb-var and all-cause mortality was substantially attenuated but remained sta- Table 3 ). As shown in Figure 1a , higher levels of Hb-var treated as a continuous variable were monotonically associated with higher all-cause mortality.
In subgroup analyses, higher Hb-var was associated with higher all-cause mortality across most subgroups (online suppl. Fig. 2 ). Race significantly modified the association of Hb-var with all-cause mortality, with greater association of higher Hb-var with all-cause mortality among African-Americans. Results were similar after further adjustment for serum ferritin level and using inpatient or outpatient Hb values separately to calculate the variability, albeit with borderline significance (online suppl. Tables 2a-4a) .
Association of Pre-ESRD Hb-var with Post-ESRD Cardiovascular and Infection-Related Mortality
During a median follow-up of 1.3 years (IQI 0.6-2.3 years) following dialysis initiation, 1,045 and 382 deaths occurred from cardiovascular and infection-related causes, respectively. In the demographically adjusted model, Hb-var quartiles were incrementally associated with cardiovascular mortality, with significantly higher death risks seen in higher Hb-var quartiles. This association was considerably attenuated and no longer significant after further adjustment for other potential confounders (adjusted Table 4 ). In contrast, higher Hb-var quartiles were Table  4 ). When using restricted cubic spline models, there was a weak but nonsignificant reverse U-shaped association of Hb-var with cardiovascular mortality (Fig. 1b) ; while the pattern of association between Hb-var and infectionrelated mortality was qualitatively similar to that with allcause mortality, with higher mortality seen in those with higher Hb-var (Fig. 1c) .
In subgroup analyses, the pattern of associations of Hb-var with cardiovascular and infection-related mortality were generally consistent across selected subgroups (online suppl. Fig. 1b, c) , with a few exceptions: the risk of infection-related mortality associated with higher Hbvar was greater in patients with eGFR <15 mL/min/1.73 m 2 and those treated with ESAs, with statistically significant interactions. The associations were robust to additional adjustment for serum ferritin levels and when using inpatient or outpatient Hb values separately to calculate the variability (online suppl. Tables 2b-4c).
Discussion
In this large national cohort of 11,872 US veterans with advanced NDD-CKD transitioning to dialysis, we found that higher Hb-var was independently associated with higher all-cause and infection-related mortality, but not cardiovascular mortality, following dialysis initiation. Compared with patients in the lowest Hb-var quartile (<0.46 g/dL), those in the highest Hb-var quartile (≥0.96 g/dL) had 10 and 28% higher all-cause and infection-related mortality, respectively, after adjusting for various potential confounders. During the 6-month prelude period, we also found that history of peptic ulcer disease or malignancy, use of iron and antiplatelet agents, dialysis catheter use, and higher number of Hb measurements and levels of baseline Hb, change in Hb, eGFR, and serum ferritin were all associated with higher Hb-var.
These results are similar to some aspects of several previous studies that reported the association of greater Hb-var with poor survival, almost exclusively in patients undergoing maintenance hemodialysis [9] [10] [11] [12] [13] [14] [15] [16] . Recently, a few observational studies have also demonstrated a similar Hb-var-mortality association in NDD-CKD populations [7, 8] , suggesting its prognostic implications throughout different stages of CKD. Most importantly, however, no previous studies have examined the Hb-var-mortality association during the ESRD transition period. The extremely high mortality experienced by incident ESRD patients immediately following transition to dialysis [17] makes the assessment of modifiable pre-transition risk factors (such as Hb-var, and others) especially important in order to find treatment targets that might have a positive effect on their survival.
Several possible explanations have been proposed for the underlying mechanisms of high Hb-var, such as differences in pharmacokinetic and bioavailability parameters among drugs that modulate Hb synthesis (e.g., ESAs and iron) [28, 29] , a high number of comorbidities, intercurrent events, and hospitalizations [9] , anemia management practice patterns, and reimbursement policies [30] . In line with these findings, we identified several clinical factors associated with higher prelude Hbvar, including history of peptic ulcer disease or malignancy, use of iron and antiplatelet agents, dialysis catheter use, and higher number of Hb measurements a Linear trend across the quartiles using the median Hb variability value of each quartile. Data are presented as number (percentage) or hazard ratio (95% CI) unless otherwise specified. Models are as follows: model 1 is adjusted for age, sex, race/ethnicity, and marital status; model 2 is adjusted for the variables in model 1 plus comorbidities (diabetes mellitus, cardiovascular disease, congestive heart failure, peripheral vascular disease, lung disease, peptic ulcer disease, liver disease, malignancy, and HIV/AIDS), Charlson comorbidity index, and cumulative length of hospitalization; and model 3 is adjusted for the variables in model 2 plus medications (ESAs, intravenous or oral iron, vitamin D analogs, ACEIs/ARBs, antiplatelets, and warfarin), eGFR levels averaged over the six-month prelude period, type of vascular access (arteriovenous fistula, arteriovenous graft, or catheter), Hb variability parameters (baseline Hb level and change in Hb), and number of Hb measurements during the 6-month prelude period.
ACEI, angiotensin-converting enzyme inhibitor; AIDS, acquired immunodeficiency syndrome; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; ESA, erythropoietin stimulating agent; Hb, hemoglobin; HIV, human immunodeficiency virus.
DOI: 10.1159/000484356 and levels of baseline Hb, change in Hb, eGFR, and serum ferritin. The substantial attenuation observed in our mortality risk estimates after accounting for all of these factors may, in turn, support their potential involvement as underlying pathophysiological mechanisms in the Hb-var-mortality relationship. In fact, patients with advanced NDD-CKD have an exceptionally high burden of numerous comorbidities, and higher prelude Hb-var may merely be a marker of more severe underlying comorbid conditions with concomitant chronic anemia requiring iron and/or ESAs supplementation, which could consequently contribute to the higher risk of all-cause mortality.
It has been suggested that increased Hb-var can also serve as a potential direct mediator of organ dysfunction or injury by repeated episodes of relative ischemia to vital organs and Hb overshoot, the former causing left ventricular dilation or hypertrophy through the development of pathologic changes of myocardium [31, 32] , the latter resulting in elevated blood pressure with risk for hypertensive encephalopathy [33] , increased thrombotic events [2] , and accelerated left ventricular dysfunction and hypertrophy [34] , mostly in patients receiving hemodialysis. In the range of Hb levels typically encountered in the NDD-CKD population, anemia as a cause of solid organ dysfunction mediated by ischemia would be unusual, which could explain why we observed less contributions of prelude Hb-var to the risk of cardiovascular mortality than infection-related mortality following dialysis initiation. This seemingly counterintuitive observation might also be partly explained by survivorship bias in this unique study population, such that patients who had suffered from the abovementioned cardiovascular complications and had higher Hb-var may have died before reaching ESRD.
Meanwhile, our findings on the association between Hb-var and infection-related mortality are generally consistent with a few previous studies that investigated the relationship between Hb-var and incidence of infectious diseases [9, 16] . Although we cannot infer a causal relationship from observational studies, there are some plausible explanations linking higher Hb-var to the risk of infection. In the present study, despite almost identical levels of baseline Hb across Hb-var quartiles, we observed higher serum ferritin levels and a higher prevalence of patients who used iron and ESAs in higher (vs. lower) Hbvar quartiles, which may have reflected underlying systemic inflammation due to infections among patients with higher Hb-var. Increase in systemic inflammation may inhibit erythropoiesis and result in a blunted or absent response to ESAs despite its high-dose administration. This ESA hyporesponsiveness, which itself is also an independent risk factor for poor survival [35] , may trigger the use of more iron because of the low transferrin saturation levels which result from inflammatory blockade of reticuloendothelial stores of iron [36] . Iron administration is highly effective in replenishing iron stores to accelerate erythropoiesis, but its excessive use may in turn result in impaired host innate immune response [37, 38] . Indeed, iron overload has been shown to promote apoptosis of helper CD4 + T lymphocytes through iron-induced oxidative stress [39, 40] and impair phagocytic and bactericidal capacities of polymorphonuclear leukocytes [41] [42] [43] ; thereby increasing susceptibility to infections. These underlying mechanisms could synergistically contribute to a higher risk of infection-related mortality. In our study, however, the association of Hb-var with infection-related mortality still remained statistically significant even after accounting for serum ferritin levels and use of ESAs and iron as well as various potential confounders, suggesting that higher prelude Hb-var could be a harbinger of future deaths from infectious causes independent of known risk factors. Given the considerable uncertainties about the physiological mechanism of Hbvar and the optimal approach to anemia management in the transition period, the effect of such interventions toward reducing Hb-var on patient outcomes may deserve further investigation.
Our study results must be interpreted in light of several limitations. First, our cohort consisted predominantly of male US veterans; hence, generalization of the results to women or patients from other geographical areas needs to be undertaken cautiously. Second, the effect of longitudinal changes in Hb-var and other potential confounders such as ESA use and iron status over the post-ESRD follow-up period was not accounted for; therefore, it is possible that such time-dependent factors might affect the observed associations. However, given the unique nature of this study which examined the impact of pre-ESRD Hb-var on post-ESRD outcomes, the observed results with the use of fixed prelude baseline covariates would still be of value, providing potential prognostic implications for post-ESRD outcomes in patients with advanced NDD-CKD.
Finally, as with all observational studies, we cannot eliminate the possibility of unmeasured confounders such as proteinuria.
In conclusion, in this large national cohort of US veterans with advanced NDD-CKD transitioning to dialysis, a greater pre-ESRD Hb-var was associated with higher post-ESRD mortality, especially with infection-related mortality. Our findings broaden the recognition of the prognostic importance of Hb-var in the immediate pre-ESRD period on post-ESRD outcomes and suggest the need for careful attention to high Hb-var in CKD patients during the transition period. Further research is required to clarify the underlying mechanisms and to test whether modification of pre-ESRD Hb-var can improve clinical outcomes in incident ESRD patients.
